CytoMed Therapeutics (GDTC) Competitors $1.90 +0.01 (+0.53%) Closing price 07/24/2025 03:49 PM EasternExtended Trading$1.92 +0.03 (+1.32%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock GDTC vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. CytoMed Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and CytoMed Therapeutics (NASDAQ:GDTC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Do institutionals & insiders believe in ATNFW or GDTC? 0.0% of CytoMed Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, ATNFW or GDTC? 180 Life Sciences has higher earnings, but lower revenue than CytoMed Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACytoMed Therapeutics$69.50K299.07-$1.84MN/AN/A Does the media refer more to ATNFW or GDTC? In the previous week, CytoMed Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for CytoMed Therapeutics and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.89 beat CytoMed Therapeutics' score of 0.82 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive CytoMed Therapeutics Positive Is ATNFW or GDTC more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A CytoMed Therapeutics N/A N/A N/A Do analysts prefer ATNFW or GDTC? CytoMed Therapeutics has a consensus target price of $5.00, indicating a potential upside of 163.16%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytoMed Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCytoMed Therapeutics beats 180 Life Sciences on 6 of the 7 factors compared between the two stocks. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.68M$3.05B$5.72B$9.47BDividend YieldN/A2.40%4.60%3.99%P/E RatioN/A20.8627.9419.95Price / Sales299.07317.05452.94100.82Price / CashN/A43.2336.5558.97Price / Book3.118.308.645.90Net Income-$1.84M-$55.19M$3.24B$258.42M7 Day Performance-6.86%5.81%3.69%2.11%1 Month Performance-18.10%17.73%10.33%12.44%1 Year Performance-3.55%4.67%34.30%19.55% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics1.5321 of 5 stars$1.90+0.5%$5.00+163.2%-5.5%$20.68M$69.50K0.00N/AUpcoming EarningsHigh Trading VolumeATNFW180 Life SciencesN/A$0.01-6.3%N/A+11.8%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.14+16.8%N/AN/A$0.00$106.21K0.0040Positive NewsGap UpALVOWAlvotechN/A$1.59-3.6%N/A-27.2%$0.00$585.60M0.004Positive NewsGap UpARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.04+75.5%N/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.10-11.4%N/AN/A$0.00$38.00M0.0070Positive NewsGap DownBTMDWbioteN/A$0.01+20.0%N/A-97.2%$0.00$199.38M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.03-31.8%N/A-65.8%$0.00N/A0.008Positive NewsGap Up Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ARAV Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDTC) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.